Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 4Breast Neoplasms 3Thyroid Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Renal Cell 2Carcinoma, Medullary 2Thyroid cancer, medullary 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Pleural Effusion 1Peritoneal Neoplasms 1Neuroblastoma 1Mesothelioma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Adenocarcinoma, Follicular 1Adenocarcinoma Of Esophagus 1

Interventions

Sunitinib 27Nivolumab 26pembrolizumab 23Sorafenib 17Everolimus 14Cyclophosphamide 13Interleukin-2 10Bevacizumab 10Radiosurgery 9spartalizumab 8pazopanib 7atezolizumab 7Ipilimumab 7Axitinib 7fludarabine 6aldesleukin 6cabozantinib 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Immunohistochemistry 5Gemcitabine 5peginterferon alfa-2b 4avelumab 4Nephrectomy 4Irinotecan 4Introns 4Gene Expression Profiling 4Capecitabine 4lenvatinib 3fludarabine phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Renal Cell × vandetanib × Clear all
NCT02495103 2021-01-26

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
7 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell

NCT01372813 2015-10-23

Vandetanib to Treat Advanced Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
3 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡